Our top pick for
Colfax Corporation is a specialty industrial machinery business based in the US. Colfax Corporation shares (CFX) are listed on the NYSE and all prices are listed in US Dollars. Colfax Corporation employs 15,400 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$22.30 - $50.26|
|50-day moving average||$45.04|
|200-day moving average||$39.39|
|Wall St. target price||$51.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.31|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Colfax Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Colfax Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Colfax Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 146x. In other words, Colfax Corporation shares trade at around 146x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Colfax Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.935. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Colfax Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Colfax Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $453.8 million.
The EBITDA is a measure of a Colfax Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3.1 billion|
|Operating margin TTM||6.92%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||1.8%|
|Return on equity TTM||1.81%|
|Market capitalisation||$6.1 billion|
TTM: trailing 12 months
There are currently 14.6 million Colfax Corporation shares held short by investors – that's known as Colfax Corporation's "short interest". This figure is 8.3% down from 15.9 million last month.
There are a few different ways that this level of interest in shorting Colfax Corporation shares can be evaluated.
Colfax Corporation's "short interest ratio" (SIR) is the quantity of Colfax Corporation shares currently shorted divided by the average quantity of Colfax Corporation shares traded daily (recently around 1.9 million). Colfax Corporation's SIR currently stands at 7.48. In other words for every 100,000 Colfax Corporation shares traded daily on the market, roughly 7480 shares are currently held short.
However Colfax Corporation's short interest can also be evaluated against the total number of Colfax Corporation shares, or, against the total number of tradable Colfax Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Colfax Corporation's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Colfax Corporation shares in existence, roughly 110 shares are currently held short) or 0.1346% of the tradable shares (for every 100,000 tradable Colfax Corporation shares, roughly 135 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Colfax Corporation.
Find out more about how you can short Colfax Corporation stock.
We're not expecting Colfax Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Colfax Corporation's shares have ranged in value from as little as $22.3 up to $50.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Colfax Corporation's is 2.2157. This would suggest that Colfax Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine/life sciences, pipelines, mobile/off-highway equipment, oil, gas, and mining markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.